Artículos científicos publicados por los investigadores del Barcelonaβeta Brain Research Center (BBRC), relacionados con la enfermedad de Alzheimer, neuroimagen, memoria y enfermedades neurodegenerativas, entre otros campos.
Pemberton HG, Collij LE, Heeman F, Bollack A, Shekari M, Salvadó G, Alves IL, Garcia DV, Battle M, Buckley C, Stephens AW, Bullich S, Garibotto V, Barkhof F, Gispert JD, Farrar G
Amyloid-β (Aβ) pathology is one of the earliest detectable brain changes in Alzheimer's disease (AD) pathogenesis. The overall load and spatial distribution of brain Aβ can be determined in vivo using...
Gonneaud J, Moreau I, Felisatti F, Arenaza-Urquijo E, Ourry V, Touron E, de la Sayette V, Vivien D, Chételat G
Introduction: Physical inactivity and female sex are independently associated with increased Alzheimer's disease (AD) lifetime risk. This study investigates the possible interactions between sex and...
Visser PJ, Reus LM, Gobom J, Jansen I, Dicks E, van der Lee SJ, Tsolaki M, Verhey FRJ, Popp J, Martinez-Lage P, Vandenberghe R, Lleó A, Molinuevo JL, Engelborghs S, Freund-Levi Y, Froelich L, Sleegers K, Dobricic V, Lovestone S, Streffer J, Vos SJB, Bos I
Background: Increased total tau (t-tau) in cerebrospinal fluid (CSF) is a key characteristic of Alzheimer's disease (AD) and is considered to result from neurodegeneration. T-tau levels, however, can...
Salvadó G, Shekari M, Falcon C, Operto G, Milà-Alomà M, Sánchez-Benavides G, Cacciaglia R, Arenaza-Urquijo E, Niñerola-Baizán A, Perissinotti A, Minguillon C, Fauria K, Kollmorgen G, Suridjan I, Molinuevo JL, Zetterberg H, Blennow K, Suárez-Calvet M, Gispert JD
Higher grey matter volumes/cortical thickness and fluorodeoxyglucose uptake have been consistently found in cognitively unimpaired individuals with abnormal Alzheimer's disease biomarkers compared...
Rambla J, Baudis M, Ariosa R, Beck T, Fromont LA, Navarro A, Paloots R, Rueda M, Saunders G, Singh B, Spalding JD, Törnroos J, Vasallo C, Veal CD, Brookes AJ
Beacon is a basic data discovery protocol issued by the Global Alliance for Genomics and Health (GA4GH). The main goal addressed by version 1 of the Beacon protocol was to test the feasibility of...
Collij LE, Salvadó G, Wottschel V, Mastenbroek SE, Schoenmakers P, Heeman F, Aksman L, Wink AM, Berckel BNM, van de Flier WM, Scheltens P, Visser PJ, Barkhof F, Haller S, Gispert JD, Alves IL
Background and objectives: Currently, amyloid-β (Aβ) staging models assume a single spatial-temporal progression of amyloid accumulation. We assessed evidence for Aβ accumulation subtypes by applying...
Pilat D, Paumier JM, García-González L, Louis L, Stephan D, Manrique C, Khrestchatisky M, Di Pasquale E, Baranger K, Rivera S
Background: Membrane-type matrix metalloproteinase 5 (MT5-MMP) deficiency in the 5xFAD mouse model of Alzheimer's disease (AD) reduces brain neuroinflammation and amyloidosis, and prevents deficits in...
Markiewicz PJ, da Costa-Luis C, Dickson J, Barnes A, Krokos G, MacKewn J, Clark T, Wimberley C, MacNaught G, Yaqub MM, Gispert JD, Hutton BF, Marsden P, Hammers A, Reader AJ, Ourselin S, Herholz K, Matthews JC, Barkhof F
Purpose: A novel phantom-imaging platform, a set of software tools, for automated and high-precision imaging of the American College of Radiology (ACR) positron emission tomography (PET) phantom for...
Cacciaglia R, Salvadó G, Molinuevo JL, Shekari M, Falcon C, Operto G, Suárez-Calvet M, Milà-Alomà M, Sala A, Rodriguez-Vieitez E, Kollmorgen G, Suridjan I, Blennow K, Zetterberg H, Gispert JD
Amyloid (Aβ) pathology is the earliest detectable pathophysiological event along the Alzheimer's continuum, which can be measured both in the cerebrospinal fluid (CSF) and by Positron Emission...